GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » Other Current Assets

OKYO Pharma (OKYO Pharma) Other Current Assets : $0.17 Mil (As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma Other Current Assets?

OKYO Pharma's other current assets for the quarter that ended in Mar. 2023 was $0.17 Mil.

OKYO Pharma's quarterly other current assets declined from Mar. 2022 ($0.71 Mil) to Sep. 2022 ($0.52 Mil) and declined from Sep. 2022 ($0.52 Mil) to Mar. 2023 ($0.17Mil).

OKYO Pharma's annual other current assets increased from Mar. 2021 ($0.02 Mil) to Mar. 2022 ($0.71 Mil) declined from Mar. 2022 ($0.71 Mil) to Mar. 2023 ($0.17 Mil).


OKYO Pharma Other Current Assets Historical Data

The historical data trend for OKYO Pharma's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma Other Current Assets Chart

OKYO Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 0.02 0.71 0.17

OKYO Pharma Semi-Annual Data
Sep13 Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.04 0.71 0.52 0.17

OKYO Pharma Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


OKYO Pharma Other Current Assets Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


OKYO Pharma (OKYO Pharma) Business Description

Traded in Other Exchanges
Address
14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Executives
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: Chief Executive Officer
Gabriele M Cerrone director, 10 percent owner, officer: Executive Chairman 265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer director C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon director PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah officer: Chief Financial Officer 55 PARK LANE, LONDON X0 W1K 1NA